Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients

Details

Serval ID
serval:BIB_3A10AEB3C6E9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients
Journal
International Journal of Radiation Oncology, Biology, Physics
Author(s)
Ozsahin  M., Tsang  R. W., Poortmans  P., Belkacemi  Y., Bolla  M., Dincbas  F. O., Landmann  C., Castelain  B., Buijsen  J., Curschmann  J., Kadish  S. P., Kowalczyk  A., Anacak  Y., Hammer  J., Nguyen  T. D., Studer  G., Cooper  R., Sengoz  M., Scandolaro  L., Zouhair  A.
ISSN
0360-3016 (Print)
Publication state
Published
Issued date
01/2006
Volume
64
Number
1
Pages
210-7
Notes
Journal Article
Multicenter Study --- Old month value: Jan 1
Abstract
PURPOSE: To assess the outcomes and patterns of failure in solitary plasmacytoma (SP). METHODS AND MATERIALS: The data from 258 patients with bone (n = 206) or extramedullary (n = 52) SP without evidence of multiple myeloma (MM) were collected. A histopathologic diagnosis was obtained for all patients. Most (n = 214) of the patients received radiotherapy (RT) alone; 34 received chemotherapy and RT, and 8 surgery alone. The median radiation dose was 40 Gy. The median follow-up was 56 months (range 7-245). RESULTS: The median time to MM development was 21 months (range 2-135), with a 5-year probability of 45%. The 5-year overall survival, disease-free survival, and local control rate was 74%, 50%, and 86%, respectively. On multivariate analyses, the favorable factors were younger age and tumor size <4 cm for survival; younger age, extramedullary localization, and RT for disease-free survival; and small tumor and RT for local control. Bone localization was the only predictor of MM development. No dose-response relationship was found for doses >30 Gy, even for larger tumors. CONCLUSION: Progression to MM remains the main problem. Patients with extramedullary SP had the best outcomes, especially when treated with moderate-dose RT. Chemotherapy and/or novel therapies should be investigated for bone or bulky extramedullary SP.
Keywords
Analysis of Variance Bone Neoplasms/mortality/pathology/*radiotherapy Disease Progression Disease-Free Survival Female Humans Male Middle Aged Multiple Myeloma/pathology Plasmacytoma/mortality/pathology/*radiotherapy Radiotherapy Dosage Retrospective Studies Treatment Outcome
Pubmed
Web of science
Create date
24/01/2008 17:20
Last modification date
20/08/2019 13:29
Usage data